Psychedelic trips could soon be part of therapy — here’s what those sessions will look like

Medicinal uses for psilocybin include depression, PTSD and other mental disorders, and as more clinical data comes in, a recent spate of public offering has raised billions of dollars for the emerging mental health field.The Washington Post | The Washington Post | Getty Images

Investors are opening their minds and wallets to the possibilities of psychedelic-assisted therapies.

Three biopharmaceutical companies aiming to make psychedelic drugs to treat mental health disorders have gone public in recent months: Peter Thiel-backed Atai Life Sciences IPO’d in June and now has a market cap of $2.6 billion; MindMed went public in April and now has a market cap of more than $1 billion; and Compass Pathways IPO’d in November, with a current market cap of nearly $1.5 billion. Keep Reading